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http:WHAT THIS PAPER ADDS
The role of thrombophilia in patients with peripheral arterial disease (PAD) remains controversial. In this
comprehensive systematic review, an association between prothrombin G20210A and those with PAD pre-
senting with critical limb ischemia is shown. The role of prothrombin G20210A as a future predictor of critical
limb ischemia in patients with PAD should be evaluated in prospective cohort studies.Objective/Background: Despite being an important risk factor for venous thromboembolism, the role of the
prothrombin G20210A mutation in patients with arterial disease remains unclear. The aim of this review was to
evaluate the association of prothrombin G20210A and lower extremity peripheral arterial disease (PAD).
Methods: This was a systematic review andmeta-analysis of caseecontrol studies. A systematic review of electronic
databases, including MEDLINE and Embase, was conducted to assess the prevalence of prothrombin G20210A in
patients with lower extremity PAD.The main outcome was the prevalence of prothrombin G20210A in patients with
lower extremity PAD. The random effects model odds ratio (OR) was used as the primary outcome measure.
Results: The initial electronic search identiﬁed 168 relevant abstracts of which ﬁve studies evaluating 1,524 cases
of PAD and 1,553 controls were included. Prothrombin G20210A was found in 70 of 1,524 patients with lower
extremity PAD and 44 of 1,553 of the controls (random effects OR 1.68, 95% conﬁdence interval [CI] 0.8e3.2). In
those with critical limb ischemia (CLI), the prevalence of prothrombin G20210A was 23 of 302 compared with 31
of 1,253 of the controls (OR 3.2, 95% CI 1.6e6.1).
Conclusion: Despite ﬁnding no signiﬁcant association between lower extremity PAD and prothrombin G20210A,
the meta-analysis suggests that the prevalence of prothrombin G20210A is signiﬁcantly elevated in those with
atherosclerotic occlusive disease of the lower extremities presenting with CLI. Well-designed prospective cohort
studies evaluating the role of prothrombin G20210A as a predictor of disease progression or adverse vascular
events are highly needed.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Prothrombin G20210A is a common genetic mutation that
increases the concentration of prothrombin, and affects
0.7e4.0% of the general population.1 Despite being an
important risk factor for venous thromboembolism (VTE),2
its role in the pathogenesis of atherosclerotic disease
Prothrombin G20210A Mutation and Lower Extremity Peripheral Arterial Disease 233(especially peripheral arterial disease [PAD]) remains un-
clear.3 Recent studies and systematic reviews have sug-
gested an association between prothrombin G20210A and
stroke (in young patients) or acute coronary syndrome.
Multiple studies providing conﬂicting results have evaluated
the prevalence of the prothrombin G20210A gene in pa-
tients with lower extremity PAD,4 and some studies have
suggested that prothrombin G20210A is more likely to affect
those with critical limb ischemia (CLI).4,5 To address this
issue, the prevalence of prothrombin G20210A in patients
with lower extremity PAD and in controls was examined.
METHODS
A systematic review of electronic databases, including
MEDLINE, PubMed, and Embase, was conducted to assess
the prevalence of prothrombin G20210A in patients with
lower extremity PAD. (The search strategies and a Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
checklist are presented as Appendices 1 and 2, respectively.)
The search was conducted for the period January 1995e
October 2014. The search was designed with the support of
a librarian from the Ottawa Hospital Health Services, and
was supplemented by a hand-search of relevant articles,
abstract books from international meetings, and published
reviews.Records idenƟfied through 
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Figure 1. Flow diagram. Note. PAD ¼ loweStudy selection
Caseecontrol studies were included if they reported the
prevalence of prothrombin G20210A in patients with lower
extremity PAD. The authors of relevant papers were con-
tacted to ensure that all the relevant data were captured. All
potentially relevant articles were reviewed in full in order to
ensure that they satisﬁed the inclusion criteria: (i) enrolment
of patients with symptomatic lower extremity PAD deﬁned as
the presence of signs and symptoms typical of lower ex-
tremity PAD (Fontaine II or higher); (ii) had conﬁrmatory
testing (including ankleebrachial index [ABI], Doppler ultra-
sound, digital subtraction angiography, or computed to-
mography angiography); (iii) prothrombin G20210A
genotypingwas available for all participants; (iv) the numbers
of cases and controls with and without prothrombin
G20210A were provided in the article. Studies were excluded
if the participants did not receive objective testing for the
prothrombin G20210A mutation, or included patients with
self-reported lower extremity PAD without objective testing.Data extraction and quality assessment
Two reviewers (FV and EG) independently assessed the
eligibility of all articles identiﬁed via the initial search
strategy. A third reviewer adjudicated all discrepancies ifAddiƟonal records idenƟfied 
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(n =  1)
ds  
 
ened  
 
Records excluded  
(n = 140) 
assessed 
ity  
Excluded  
(n = 23) 
Cohort (n = 7) 
Duplicated (n = 4) 
Review (n = 7) 
Nonrelevant (n = 2) 
Unclear definiƟon of PAD 
(n = 1) 
DiagnosƟc method not 
reported (n = 1) 
 Children (n = 1) 
ed in 
thesis  
ed in 
nthesis 
sis) 
r extremity peripheral arterial disease.
Table 1. Characteristics of the studies included.
Study Deﬁnition of PAD Country PAD (n) Controls (n) Matched Ethnicity Males,
cases/controls
(%)
Smokers,
cases/controls
(%)
Hypertension,
cases/controls
(%)
Diabetes,
cases/controls
(%)
CLI (%)a
Mueller et al.
(2005)10
ABI at index < 1,
angiography
Austria 433 433b Yes White 71/71 45/12 58/41 27/27 17
Renner et al.
(2000)9
Clinical symptoms,
ABI at index < 1,
conﬁrmation by Doppler
or angiography
Austria 336 300c No d 54/48 42/23 65/29 34/13 22
Reny et al.
(2004)5
Clinical symptoms, and
ABI at index < 0.90 or
prior revascularization
France 184 330e Yes White e 97/55 52/31 24/8 14
Sartori et al.
(2010)4
Clinical symptoms, ABI at
index < 0.90, conﬁrmation
by Doppler
Italy 291 210d No White 64/58 33/10 79/37 27/4 38
Soﬁ et al.
(2005)11
Clinical symptoms, ABI
at index < 0.90
Italy 280 280f Yes e 77/77 70/20 54/15 17/2 32
Note. Quality was assessed using the NewcastleeOttawa scale. PAD ¼ lower extremity peripheral arterial disease; CLI ¼ critical limb ischemia; ABI ¼ ankleebrachial index.
a CLI deﬁned as Fontaine stages III or IV.
b No clinical indication of PAD by history and physical examination; systolic brachial blood pressure equal to or less than the blood pressure in of each of the right and left anterior tibial and
posterior tibial arteries (i.e., ABI ¼ 1.0); no pathologic pattern of pulse waves in lower limbs by continuous-wave spectral analysis; no coronary artery disease; no cardiovascular disease; no
previous vascular surgery or stenting of the internal carotid arteries; no stenosis of the internal carotid artery > 50% by color duplex ultrasound scans; no history of venous thromboembolism;
and no history or presence of any malignancy.
c Only Austrian participants without any known arterial or venous disease served.
d Age-matched controls had no history of arterial disease (stroke, myocardial infarction, angina, or PAD) and were randomly selected from 703 white men of a previously described control
group used to study genetic risk factors for vascular thrombosis.
e Only men included.
f Unrelated participants without PAD, matched for age and sex, who were recruited from the staff of the University of Florence and from partners or friends of patients.
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Prothrombin G20210A Mutation and Lower Extremity Peripheral Arterial Disease 235needed (GLG). Two independent reviewers used the New-
castleeOttawa Scale (NOS) for observational studies to
assess the methodological quality of the selected studies.6
Outcome measure
The primary outcome measure was the odds ratio (OR)
for the prevalence of patients with prothrombin G20210A
with lower extremity PAD. A prespeciﬁed subgroup anal-
ysis was conducted based on the severity of the disease,
deﬁned as intermittent claudication (deﬁned as patients
with Fontaine stage IIa/IIb) or CLI (deﬁned as patients
with Fontaine III/IV).
Data synthesis and analysis
The random effects model OR was used as the primary
outcome measure, along with the corresponding 95%
conﬁdence intervals (CIs). Pooled proportions were calcu-
lated as the back-transformation of the weighted mean of
the transformed proportions, using inverse arcsine variance
weights for the ﬁxed effects model and DerSimonianeLaird
weights for the random effects model. Transformation of
proportions into a quantity using the FreemaneTukey
variant of the arcsine square root method is suitable for
the usual ﬁxed and random effects summaries. The I2
statistic was used to quantify heterogeneity among the
pooled estimates across studies. An I2 value < 25% was
considered low-level heterogeneity, 25e50% as moderate-
level heterogeneity, and > 50% as high-level heterogeneity.
Homozygote and heterozygote carriers of prothrombin
G20210A were analyzed as one group. The statistical
analysis was performed using RevMan 5.3 (The Cochrane
Collaboration, Copenhagen, Denmark) and the Grading of
Recommendations, Assessment, Development and Evalu-
ations (GRADE) analysis was conducted using GradePRO
(www.gradepro.org).
RESULTS
The initial electronic search identiﬁed 168 relevant abstracts
(after the removal of duplicates), of which 140 were
considered nonrelevant to the search and therefore
excluded; 28 were selected for full text review. Twenty-two
were excluded for the reasons described in Fig. 1 (two
studies evaluated the prevalence of prothrombin G20210A
in patients with PAD but did not satisfy the inclusion
criteria7,8). Of the ﬁve studies selected, two were conducted
in Austria,9,10 one in France,5 and two in Italy.4,11 The
prevalence of patients with CLI varied between 14% and
38% across studies. Two of the studies, both from Austria,
included patients with an ABI < 1 (one conﬁrmed the dis-
ease with digital subtraction angiography,10 and the other
with Doppler ultrasound or angiography9), whereas the rest
of the studies included patients with an ABI < 0.9. Baseline
characteristics of cases and controls included in the studies
are presented in Table 1. The quality scores using the NOS)
are presented in Table 2.
In total, the ﬁve studies evaluated 1,524 cases of lower
extremity PAD and 1,553 controls (see Table 3 for a more
236 F. Vazquez et al.comprehensive review of the number of patients included
in each study and individual OR). Prothrombin G20210A
was found in 70 of 1,524 patients with lower extremity PAD
(random effects pooled proportion 4.7%, 95% CI 3.3e6.3;
I2 ¼ 47%) and 44 of 1,553 of the controls (random effects
pooled proportion 2.9%, 95% CI 1.8e4.15; I2 ¼ 43.9%)
(random effects OR 1.68, 95% CI 0.8e3.2 [P ¼ 0.11);
I2 ¼ 61.3%; see Fig. 2).7,8
Using data from four studies the prevalence of pro-
thrombin G20210A in those with claudication (Fontaine IIa
or IIb) or CLI (Fontaine III/IV) as separate subgroups was
analyzed.4,5,10,11 The number of patients with CLI was not
obtained for one study (no response was received to an
email sent to the authors9). The prevalence of prothrombin
G20210A was 38 of 886 in those with claudication (random
effects pooled proportion 4%, 95% CI 3.1e5.9; I2 ¼ 5.2%)
and 31 of 1,253 in the healthy controls (random effects
pooled proportion 2.6%, 95% CI 1.6e3.7; I2 ¼ 31.5%)
(random effects OR 1.8, 95% CI 0.8e3.8; I2 ¼ 55.4%; see
Fig. 3). In those with CLI the prevalence of prothrombin
G20210A was 23 of 302 (random effects pooled proportionTable 3. Total number of prothrombin G20210A (PTGM) carriers includ
Prevalence of PTGM in patients with PAD deﬁned vs. controls
Study PTGM carriers/PAD cases (n)
Mueller et al. (2005)10 16/433
Renner et al. (2000)9 9/336
Reny et al. (2004)5 12/184
Sartori et al. (2010)4 18/291
Soﬁ et al. (2005)11 15/280
Prevalence of PTGM in those with claudication (Fontaine IIa/IIb) vs.
Study PTGM carriers/PAD cases
Mueller et al. (2005)10 12/359
Reny et al. (2004)5 8/158
Sartori et al. (2010)4 6/181
Soﬁ et al. (2005)11 12/190
Prevalence of PTGM in those with CLI (Fontaine III/IV) vs. controls
Study PTGM carriers/PAD cases
Mueller et al. (2005)10 4/74
Reny et al. (2004)5 4/26
Sartori et al. (2010)4 12/110
Soﬁ et al. (2005)11 3/90
Note. PAD ¼ lower extremity peripheral arterial disease; CI ¼ conﬁde
Figure 2. Forest plot prevalence of Prothrombin G20210A in patients w
Note. CI ¼ conﬁdence interval; Mueller ¼ Mueller et al. (2005)10; Ren
et al. (2005).118%, 95% CI 3.9e13.4; I2 ¼ 55.3%) compared with 31 of
1,253 (random effects pooled proportion 2.6%, 95% CI 1.6e
3.7; I2 ¼ 31.5%) in the healthy controls (random effects OR
3.2, 95% CI 1.6e6.13; I2 ¼ 19.5%; see Fig. 4). Further,
analysis restricting by the use of matched caseecontrols did
not modify the association of prothrombin G20210A
and CLI.
Table 4 presents an analysis of the evidence using a
GRADE approach.DISCUSSION
Despite ﬁnding no association between lower extremity
PAD and prothrombin G20210A, the meta-analysis suggests
that the prevalence of prothrombin G20210A is signiﬁcantly
elevated in those with atherosclerotic occlusive disease of
the lower extremities presenting with CLI.
The association of prothrombin G20210A with athero-
sclerotic disease remains a matter of debate.12,13 Despite
the widespread belief that prothrombin G20210A is
essentially a risk factor for VTE,3,14 some meta-analyses anded in each study and individual odds ratios (OR).
PTGM carriers/controls (n) OR 95% CI
12/433 1.34 0.6e2.8
13/300 0.60 0.2e1.4
6/330 3.76 1.3e10.2
9/210 1.47 0.6e3.3
4/280 3.90 1.2e11.9
controls
PTGM carriers/controls OR 95% CI
12/433 1.21 0.5e2.7
6/330 2.88 0.9e8.4
9/210 0.76 0.2e2.1
4/280 4.65 1.4e14.6
PTGM carriers/controls OR 95% CI
12/433 2.00 0.6e6.3
6/330 9.81 2.5e37.3
9/210 2.73 1.1e6.7
4/280 2.37 0.52e10.8
nce interval; CLI ¼ critical limb ischemia.
ith lower extremity peripheral arterial disease (PAD) vs. controls.
y ¼ Reny et al. (2004)5; Sartori ¼ Sartori et al. (2010)4; Soﬁ ¼ Soﬁ
Figure 3. Forest plot prevalence of prothrombin G20210A in patients with lower extremity claudication vs. controls. Note. PAD ¼ lower
extremity peripheral arterial disease; CI ¼ conﬁdence interval; Mueller et al. (2005)10; Reny ¼ Reny et al. (2004)5; Sartori ¼ Sartori et al.
(2010)4; Soﬁ ¼ Soﬁ et al. (2005).11
Figure 4. Forest plot prevalence of prothrombin G20210A in patients with lower extremity critical limb ischemia vs. controls. Note.
PAD ¼ lower extremity peripheral arterial disease; CI ¼ conﬁdence interval; Mueller et al. (2005)10; Reny ¼ Reny et al. (2004)5;
Sartori ¼ Sartori et al. (2010)4; Soﬁ ¼ Soﬁ et al. (2005).11
Prothrombin G20210A Mutation and Lower Extremity Peripheral Arterial Disease 237large population studies have suggested that prothrombin
G20210A either alone or in combination with other genetics
variants increases the risk of stroke or coronary dis-
ease.2,15e17 To the knowledge of the authors, only one
systematic review, conducted in 2003, identiﬁed a study
addressing the association between G20210A and athero-
sclerotic occlusive disease of the lower extremities.18 The
present study identiﬁed four additional studies that show
this association and is the ﬁrst meta-analysis to show an
association between prothrombin G20210A and CLI sec-
ondary to atherosclerotic occlusive disease of the lower
extremities (as suggested by the caseecontrol studies of
Reny et al.5 in 2004 and Sartori et al.4 in 2010).
The activation of the coagulation cascade appears to in-
crease the risk of disease progression and vascular events in
patients with PAD,19e24 via multiple mechanisms.25e27
Thrombin has multiple effects. Following thrombus forma-
tion it remains abundant in mural thrombi subsequent to
vascular injury and may be important for vessel repair
processes as it appears to regulate inﬂammatory pro-
cesses.23,28,29 It also directly stimulates vascular smooth
muscle cell proliferation and migration.28,29 The prothrom-
bin G20210A mutation is located at the 30-untranslated
polyadenylation cleavage site and is associated with
increased plasma prothrombin levels.30 Others have sug-
gested prothrombin G20210A could lead to higher levels of
thrombin formation should triggering of the coagulation
cascade occurs (measured by endogenous thrombin
potential).31As with patients with VTE and those with other forms of
arterial disease, the utility of screening for prothrombin
G20210A in patients with PAD to guide prognostic or
therapeutic decisions is uncertain.3,12 Based on the data
presented herein, whether prothrombin G20210A increases
the risk of progression from claudication to CLI remains
speculative. One cohort suggested that all carriers of pro-
thrombin G20210A showed disease progression compared
with 67% of the noncarriers (this difference was nonsig-
niﬁcant, possibly owing to the small sample size). In order
to provide more deﬁnite answers regarding the role of
prothrombin G20210A in patients with PAD, large pro-
spective cohort studies are required.
The present study has limitations. First, given that the
prevalence of prothrombin G20210A varies between
different ethnicities and geographical areas,1 and that the
majority of study participants were white, the results do not
apply to ethnic groups other than the one represented in this
study (white people from Germanic and Latin European
countries). Second, the association between CLI and pro-
thrombin G20210A was based on only four studies, as it was
not possible to retrieve information from all studies.Third, by
including caseecontrol studies, it cannot be estimated if the
presence of prothrombin G20210A is associated with pro-
gression from claudication to CLI, or an increased risk of
future vascular events (especially in patients with CLI32), or
following vascular procedures. The number of studies
addressing the outcome after procedures is limited, to the
authors’ knowledge, to three small studies with < 10
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238 F. Vazquez et al.patients, all of whom were carriers of prothrombin
G20210A.31e33 Fourth, except for the analysis of CLI, all the
analyses had high heterogeneity. Fifth, claudicants and pa-
tients with CLI were divided using Fontaine stage alone.
Sixth, not all the studies used matching and, as such,
potentially introduced bias. However, the two studies that
did not use initial matching adjusted the results for relevant
characteristics. Seventh, the types of controls selected varied
across studies, although all of them excluded patients with
clinically overt vascular or thrombotic disease. Eight, the
selection of cases varied across studies. Two of the studies,
both from Austria, included patients with an ABI < 1 (one
conﬁrmed the disease with digital subtraction angiography,10
and the other with Doppler ultrasound or angiography9),
whereas the rest of the studies included patients with an
ABI < 0.9. Finally, homozygous prothrombin G20210A could
not be assessed owing to the small number of patients
affected, and the potential for potential high-risk interactions
with prothrombin G20210A, such as blood type, could not be
investigated.
CONCLUSION
This meta-analysis could not ﬁnd an association between
prothrombin G20210A and PAD, but suggests that the
prevalence of prothrombin G20210A is elevated in those
with CLI secondary to PAD. Well-designed prospective
cohort studies evaluating the role of prothrombin G20210A
as a predictor of disease progression to CLI or adverse
vascular events are highly needed.
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H.S. Rayt *, A. Nasim
University Hospitals of Leicester NHS Trust, Leicester, UKPercutaneous vertebroplasty is routinely being performed in patients with vertebral compression fractures using poly-
methylmetaacrylate cement. The cement commonly leaks into the perivertebral tissues, but only around 1% of patients
develop any clinical symptoms. The computed tomography image shows extrusion of cement into the vena cava (arrow) in a
24-year-old female treated for steroid-induced osteoporotic vertebral fracture. This was only discovered 1 week after the
procedure when the patient complained of persistent backache, which prompted the imaging. She had no lower limb
symptoms and in view of this, conservative management was pursued with anticoagulation therapy.
